Merck withdrew its lung cancer drug application. A phase 3 trial is still enrolling.
Merck and Daiichi Sankyo withdrew the Biologics License Application for ifinatamab deruxtecan in treating extensive-stage small cell lung cancer. The decision follows discussions with the FDA, but enrollment continues in a phase 3 trial. The drug is a B7-H3 directed antibody drug conjugate being jointly developed by the companies. Both firms expressed disappointment but remain committed to evaluating the drug's potential in other cancer types.
How this was made
The 30-second read
Why it matters
The withdrawal reflects regulatory concerns and may delay or cancel a potential first‑in‑class oncology therapy, affecting both companies' pipeline valuations.
Market read
The news is material for biotech investors and may trigger short‑term price declines for the involved stocks.
What to watch
Data from the ongoing phase 3 trial could still lead to a future filing; the setback may be temporary.
Background
Merck and Daiichi Sankyo announced the voluntary withdrawal of the BLA for ifinatamab deruxtecan after discussions with regulators, while enrollment continues in the phase 3 trial.
Ticker impact
Merck withdrew the Biologics License Application for ifinatamab deruxtecan in extensive-stage small cell lung cancer.
Downward pressure on MRK share price in the short term.
Withdrawal signals regulatory or data concerns; investors typically react negatively to such setbacks.
Market effects
Oncology drug development sector faces heightened scrutiny after the withdrawal.
US and Japanese pharma markets may see slight bearish sentiment.
Limited to biotech investors; broader market impact minimal.
Counterpoint
The withdrawal may allow Merck to reallocate resources to more promising assets, potentially improving long‑term pipeline strength.
Key entities
- CompanyMerck
US‑listed pharmaceutical company (ticker MRK) co‑developer of the ADC.
- CompanyDaiichi Sankyo
Japanese pharmaceutical firm (ticker 4568.T) co‑developer of the ADC.
